Search research articles
Contact Us
Filters
Showing results (61-70 of 72) with videos related to
Page
of 8
Sort By:
Nature Communications
|
October 28, 2018
IL-7 receptor blockade blunts antigen-specific memory T cell responses and chronic inflammation in primates
Lyssia Belarif, Caroline Mary, Lola Jacquemont, et al.
Science Advances
|
November 18, 2022
CLEC-1 is a death sensor that limits antigen cross-presentation by dendritic cells and represents a target for cancer immunotherapy
Marion Drouin, Javier Saenz, Vanessa Gauttier, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 15, 2011
New positive allosteric modulators of the metabotropic glutamate receptor 2 (mGluR2): identification and synthesis of N-propyl-8-chloro-6-substituted isoquinolones
Andrés A Trabanco, Guillaume Duvey, José María Cid, et al.
Cell Death Discovery
|
March 4, 2022
Concerted BAG3 and SIRPα blockade impairs pancreatic tumor growth
Margot De Marco, Vanessa Gauttier, Sabrina Pengam, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 25, 2026
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours
Marie Robert, Nuria Kotecki, Carlos Gomez-Roca, et al.
The Journal of Clinical Investigation
|
August 14, 2018
CD28 blockade controls T cell activation to prevent graft-versus-host disease in primates
Benjamin K Watkins, Victor Tkachev, Scott N Furlan, et al.
Mabs
|
May 15, 2023
10th antibody industrial symposium: new developments in antibody and adoptive cell therapies
Ana Antunes, Luis Alvarez-Vallina, Federico Bertoglio, et al.
ACS Chemical Neuroscience
|
July 11, 2012
Discovery of 1,5-disubstituted pyridones: a new class of positive allosteric modulators of the metabotropic glutamate 2 receptor
Jose María Cid, Guillaume Duvey, Philippe Cluzeau, et al.
Blood
|
March 22, 2024
The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis
Lennart Lenk, Irène Baccelli, Anna Laqua, et al.
Hemasphere
|
June 19, 2026
Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL
Denis Pinkle, Melissa Cornils, Anna Dietterle, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 72) with videos related to
Sort By:
Page
of 8
Nature Communications
|
October 28, 2018
IL-7 receptor blockade blunts antigen-specific memory T cell responses and chronic inflammation in primates
Lyssia Belarif, Caroline Mary, Lola Jacquemont, et al.
Science Advances
|
November 18, 2022
CLEC-1 is a death sensor that limits antigen cross-presentation by dendritic cells and represents a target for cancer immunotherapy
Marion Drouin, Javier Saenz, Vanessa Gauttier, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 15, 2011
New positive allosteric modulators of the metabotropic glutamate receptor 2 (mGluR2): identification and synthesis of N-propyl-8-chloro-6-substituted isoquinolones
Andrés A Trabanco, Guillaume Duvey, José María Cid, et al.
Cell Death Discovery
|
March 4, 2022
Concerted BAG3 and SIRPα blockade impairs pancreatic tumor growth
Margot De Marco, Vanessa Gauttier, Sabrina Pengam, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 25, 2026
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours
Marie Robert, Nuria Kotecki, Carlos Gomez-Roca, et al.
The Journal of Clinical Investigation
|
August 14, 2018
CD28 blockade controls T cell activation to prevent graft-versus-host disease in primates
Benjamin K Watkins, Victor Tkachev, Scott N Furlan, et al.
Mabs
|
May 15, 2023
10th antibody industrial symposium: new developments in antibody and adoptive cell therapies
Ana Antunes, Luis Alvarez-Vallina, Federico Bertoglio, et al.
ACS Chemical Neuroscience
|
July 11, 2012
Discovery of 1,5-disubstituted pyridones: a new class of positive allosteric modulators of the metabotropic glutamate 2 receptor
Jose María Cid, Guillaume Duvey, Philippe Cluzeau, et al.
Blood
|
March 22, 2024
The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis
Lennart Lenk, Irène Baccelli, Anna Laqua, et al.
Hemasphere
|
June 19, 2026
Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL
Denis Pinkle, Melissa Cornils, Anna Dietterle, et al.
Page
of 8